Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax

Can they keep outpacing the popular cryptocurrency?

2 Stocks That Are Running Circles Around Bitcoin This Year

Los Angeles, California--(Newsfile Corp. - June 17, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an...

ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.

Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.

It's Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

Ocugen Inc. Set to Join Russell 3000® Index

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 2.12% yesterday. This is why it happened.

OCGN Stock Price Increased 2.12%: Why It Happened

NEW YORK, June 15, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) resulting from allegations that Ocugen may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ocugen securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation - OCGN

OCGN stock saw a glimmer of hope today. Where the company took a hit last week in deserting EUA, it is gaining today with a new partnership.

OCGN Stock: Ocugen Fans Should Be Cheering This COVAXIN News

The biotech is bolstering its production capabilities for an experimental coronavirus vaccine.

Why Ocugen Stock Rallied Today

The shares of biopharmaceutical concern Ocugen Inc (NASDAQ:OCGN) are surging this afternoon, last seen up 7.2% to trade at $6.56.

Options Traders Speculate on OCGN After Vaccine Update

Ocugen Inc (NASDAQ: OCGN) has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVID-19 vaccine candidate, Covaxin for the U.S. and Canadian markets. "Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada," said J.P.

Ocugen Stock Jumps After Recruiting Jubilant HollisterStier As Manufacturing Partner For COVID-19 Vaccine Candidate

Shares of Ocugen Inc. gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still-investigational COVID-19 vaccine for the U.S. and Canada. The vaccine is not authorized or approved in either country at this time.

Ocugen's stock is up 14% after announcing manufacturing partner for experimental COVID-19 shot

Jubilant HollisterStier to manufacture COVAXIN™ in the US Jubilant HollisterStier to manufacture COVAXIN™ in the US

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

Ocugen Stock Crashes: What Should Investors Do Now?

Crocs

Roblox

Schrodinger 

Teladoc

XPeng

Searching for stocks to buy that could legitimately double before 2022? These seven are in position to do just that.

7 Stocks To Buy if You're Trying to Double Your Money in 2021

Boston, Massachusetts--(Newsfile Corp. - June 14, 2021) - Block & Leviton is investigating Ocugen, Inc. (NASDAQ: OCGN) for potential securities law violations. Investors who have lost money in their Ocugen investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ocgn.What is this all about?Today, Ocugen announced that it would "no longer pursue an emergency use authorization" for its COVID-19 vaccine candidate, Covaxin, and would instead...

OCUGEN INVESTIGATION: Block & Leviton Investigates Ocugen For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

This high flyer is still up more than 260% this year.

Will This News Stop Ocugen Shares in Their Tracks?

Biogen

Cara Therapeutics

It pays to know what could cause them to move and when.

How to Buy Biotech Stocks This Summer

Which Stocks Are the Biggest Losers From the FDA's COVID Vaccine Authorization Changes?

LOS ANGELES--(BUSINESS WIRE)---- $OCGN #OCGN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate.

Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks

New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) concerning possible violations of federal securities laws. To view an enhanced version of this graphic, please visit:

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ocugen, Inc.

GT Biopharma Inc

Novan

Vaxart

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

The stock price of Ocugen Inc (NASDAQ: OCGN) fell by 28.14% today. This is why it happened.

News for Ocugen, Inc. Stock (OCGN)